...
首页> 外文期刊>Cancer Cell International >CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)
【24h】

CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)

机译:CircRNA CDR1AS / miR-641 / Hoxa9途径管杆菌有助于非小细胞肺癌(NSCLC)中的顺铂抗性

获取原文
           

摘要

Cisplatin (DDP) is the first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), and long-term DDP stimulation increased resistance of NSCLC cells to this drug by enriching cancer stem cells (CSCs), which contributed to recurrence and worse prognosis of NSCLC, but the molecular mechanisms are still not fully delineated. Real-Time qPCR and Western Blot analysis were conducted to examine gene expressions at mRNA and protein levels, respectively. Dual-luciferase reporter gene system was used to validate the targeting sites among circRNA CDR1as, miR-641 and HOXA9 mRNA. Cell growth was evaluated by CCK-8 assay, trypan blue staining assay and colony formation assay. The Annexin V-FITC/PI double staining method was employed to measure cell apoptosis ratio. Spheroid formation and flow cytometer assay was used to evaluate cell stemness. Xenograft mice models were established to measure tumorgenicity in vivo, and Ki67 expressions in mice tumor tissues were examined by immunohistochemistry (IHC). Here we identified a novel circRNA CDR1as/miR-641/Homeobox protein Hox-A9 (HOXA9) pathway regulated stemness and DDP chemoresistance in NSCLC. Mechanistically, circRNA CDR1as and HOXA9 were high-expressed, while miR-641 was low-expressed in DDP-resistant NSCLC cells, instead of their corresponding parental DDP-sensitive NSCLC cells. Additionally, we validated that circRNA CDR1as positively regulated HOXA9 in NSCLC cells by serving as an RNA sponge for miR-641, and knock-down of circRNA CDR1as increased the sensitivity of DDP-resistant NSCLC cells, which were reversed by downregulating miR-641 and upregulating HOXA9. Consistently, overexpression of circRNA CDR1as increased drug resistance of DDP-sensitive NSCLC cells by regulating miR-641/HOXA9 axis. In addition, the expression levels of stemness signatures (SOX2, OCT4 and Nanog) were higher in DDP-resistant NSCLC cells, which also tended to form spheres and enrich CD44+CD166+ population compared to their parental DDP-sensitive NSCLC cells, suggesting that CSCs were enriched in DDP-resistant NSCLC cells. Notably, knock-down of circRNA CDR1as inhibited stemness of DDP-resistant NSCLC cells by inhibiting HOXA9 through upregulating miR-641. Taken together, this study identified that circRNA CDR1as regulated stemness and DDP chemoresistance in NSCLC cells by targeting miR-641/HOXA9 axis.
机译:顺铂(DDP)是一种用于非小细胞肺癌(NSCLC)的一线化学治疗药物,通过富集癌症干细胞(CSC),长期DDP刺激通过富集癌症干细胞(CSC)来增加NSCLC细胞对该药物的抗性,这有助于复发和更糟糕的NSCLC预后,但分子机制仍未完全划定。进行实时QPCR和Western印迹分析以分别检查mRNA和蛋白质水平的基因表达。双荧光素酶报告基因系统用于验证CircrNA CDR1As,miR-641和Hoxa9 mRNA中的靶向位点。通过CCK-8测定,台盼蓝染色测定和菌落形成测定评估细胞生长。使用膜蛋白V-FITC / PI双染色方法来测量细胞凋亡率。球形形成和流式细胞计测定用于评估细胞茎。建立了异种移植小鼠模型以测量体内肿瘤性,并通过免疫组织化学(IHC)检查小鼠肿瘤组织中的Ki67表达。在这里,我们鉴定了一种新的CircrNA CDR1AS / miR-641 / Homeobox蛋白Hox-A9(Hoxa9)途径调节的茎干和NSCLC中的DDP Chemiolatyisce。机械地,CircRNA CDR1As和Hoxa9高表达,而MiR-641在DDP抗性NSCLC细胞中低表达,而不是它们相应的亲本DDP敏感NSCLC细胞。此外,我们通过用作miR-641的RNA海绵,验证CircrNA CDR1as在NSCLC细胞中呈正常调节Hoxa9,并且CircrNA CDR1A的敲低增加了DDP抗性NSCLC细胞的敏感性,通过下调MiR-641和逆转上调霍索拉9。一致地,通过调节miR-641 / hoxa9轴来抑制CircrNA CDR1as的过表达增加了DDP敏感NSCLC细胞的耐药性。此外,DDP抗性NMSCLC细胞中茎差异(SOX2,OCT4和NANOG)的表达水平较高,该细胞也倾向于与其亲生DDP敏感的NMSCLC细胞相比倾向于形成球体并富集CD44 + CD166 +群体,表明CSCs富含DDP抗性NSCLC细胞。值得注意的是,通过上调miR-641抑制Hoxa9,CircrNA CDR1as的敲低抑制DDP抗性NMSCLC细胞的茎。在一起,该研究通过靶向miR-641 / hoxa9轴来确定CircrNA CDR1AS调节NSCLC细胞中的茎和DDP化学渗透度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号